Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Raman Puri, Manish Bansal, Vimal Mehta, P Barton Duell, Nathan D Wong, S S Iyengar, Dinesh Kalra, Devaki R Nair, Navin C Nanda, Jagat Narula, P Deedwania, Jamal Yusuf, Jamshed J Dalal, Sadanand Shetty, Vinod M Vijan, Rajeev Agarwala, Soumitra Kumar, Kris Vijay, Aziz Khan, Gurpreet Singh Wander, P C Manoria, S K Wangnoo, Viswanathan Mohan, Shashank R Joshi, Balbir Singh, Prafulla Kerkar, Rajesh Rajput, D Prabhakar, Abdul Hamid Zargar, Banshi Saboo, Ravi R Kasliwal, Saumitra Ray, Sandeep Bansal, M U Rabbani, Shibba Takkar Chhabra, Sarat Chandra, Neil Bardoloi, Narasaraju Kavalipati, Immaneni Sathyamurthy, Kunal Mahajan, Akshya Pradhan, N N Khanna, Rajesh Khadgawat, Preeti Gupta, Milan C Chag, Ashu Gupta, A Murugnathan, S N Narasingan, Sundeep Upadhyaya, Vinod Mittal, Rashida Patanwala Melinkeri, Madhur Yadav, M Raseed Mubarak, K K Pareek, Pradeep Kumar Dabla, Rashmi Nanda, J C Mohan
OBJECTIVE: In 2016, the Lipid Association of India (LAI) developed a cardiovascular risk assessment algorithm and defined low-density lipoprotein cholesterol (LDL-C) goals for prevention of atherosclerotic cardiovascular disease (ASCVD) in Indians. The recent refinements in the role of various risk factors and subclinical atherosclerosis in prediction of ASCVD risk necessitated updating the risk algorithm and treatment goals. METHODS: The LAI core committee held twenty-one meetings and webinars from June 2022 to July 2023 with experts across India and critically reviewed the latest evidence regarding the strategies for ASCVD risk prediction and the benefits and modalities for intensive lipid lowering...
February 8, 2024: Journal of Clinical Lipidology
#22
JOURNAL ARTICLE
Touseef Iqbal, Muhammad Sohaib, Sanaullah Iqbal, Habib Rehman
The mushrooms oyster ( Pleurotus ostreatus ) and white button ( Agaricus bisporus ) contain bioactive compounds that have potential beneficial effects on hypercholesterolemia and cardiovascular diseases. In this study, hypolipidemic and antioxidative potential of these mushrooms' extract were explored using hypercholesterolemic (HC) rats as animal model. For the study, 56 adult rats were divided into seven groups, i.e., G1 (negative control), G2 (positive control group), G3 (HC rats with statin drug orally), G4 and G5 (HC rats @ 100 and 200 mg/kg body weight (BW) dose of oyster mushroom extracts), and G6 and G7 (HC rats @ 100 and 200 mg/kg BW dose of white button mushroom extracts)...
February 26, 2024: Foods (Basel, Switzerland)
#23
JOURNAL ARTICLE
Wenjing Zhou, Zhuoru Liang, Xiaohuan Lou, Nansong Wang, Xinyu Liu, Ruoxi Li, Pearl Pai
Objective: Statin is well-established as a classical lipid-lowering drug, and its cost has reduced considerably in the past years. Inclisiran is a new and effective lipid-lowering drug given as a subcutaneous injection at 6-month intervals. This study aims to evaluate the cost-effectiveness of the combination use of inclisiran and statin versus statin alone for dyslipidemia in the mainland China population. Methods: The Markov decision-making model was used, and the clinical data and real-world data were collected at the University of Hong Kong-Shenzhen Hospital (HKU-SZH)...
2024: Frontiers in Pharmacology
#24
JOURNAL ARTICLE
Pineal Yitbarek Fisseha, Assefa Mulu Baye, Melak Gedamu Beyene, Eyasu Makonnen
BACKGROUND: Diabetes mellitus (DM) increases cardiovascular disease (CVD) incidence and mortality. While guidelines endorse statin use in type 2 DM (T2DM) to mitigate cardiovascular risks and mortality, challenges like statin initiation and prompt treatment adjustments affect patient outcomes. This study aimed to assess the appropriateness of indications for and dose intensification of statin therapy among T2DM patients at Tikur Anbessa Specialized Hospital (TASH). METHODOLOGY: A hospital-based cross-sectional study was conducted from April 1 to June 30 2020...
2024: Diabetes, Metabolic Syndrome and Obesity
#25
JOURNAL ARTICLE
Sipan Sarbast, Jamal B Mohamad
Introduction Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of mortality globally, according to the World Health Organization. Research from the Middle East indicates that cardiovascular disease-related deaths in the region are among the highest worldwide. Multiple risk factors contribute to ASCVD. Elevated low-density lipoprotein cholesterol (LDL-C), often associated with hyperlipidemia, plays a pivotal role. The reduction of LDL cholesterol through statins has been extensively studied over the years and has demonstrated a significant decrease in rates of cardiovascular disease, particularly in high- and very high-risk groups...
February 2024: Curēus
#26
JOURNAL ARTICLE
Julia Bianca Bardoczi, Michael Rossen, Nadia Eugster, Thomas Agoritsas, Baris Gencer, Nicolas Rodondi
Dyslipidemia is a modifiable risk factor for cardiovascular diseases. Recommendations are based on achieving LDL-C target levels, but it is essential to assess the benefits of intensifying lipid-lowering therapy in terms of absolute risk reduction of cardiovascular events across different risk groups. Current data on the absolute benefits of the latest lipid-lowering treatments are more limited in comparison with statins. A recent analysis showed that adding a second lipid-lowering treatment only reduces the absolute cardiovascular risk in patients at very high and high cardiovascular risk, without a substantial benefit in patients at moderate or low cardiovascular risk, as mentioned in the recent recommendations free of conflict of interest and published in the British Medical Journal...
March 6, 2024: Revue Médicale Suisse
#27
Lai Zhong Yang, Qi Zhe Ngoo, Vithiaa Nilamani, Rafidah Sudarno
We report a case of central retinal artery occlusion with concurrent ischemic stroke in a young patient. A 34-year-old Malay gentleman, an ex-smoker with underlying dyslipidemia, however, not on medication or follow-up, presented with acute, generalized, and painless right eye blurring of vision for one day. He also complained of on-and-off headaches for the past three months prior to the presentation. Visual acuity assessment demonstrated hand movement in the right eye, whereas in the left eye, it was 6/6, along with a right eye relative afferent pupillary defect...
February 2024: Curēus
#28
JOURNAL ARTICLE
Junya Aoki, Kazumi Kimura
Objective Although the body mass index (BMI) is considered a meaningful parameter for evaluating obesity, the association between the BMI and acute non-cardioembolic stroke remains unclear. We investigated how the BMI was related to patients' background, type of infarction, and infarction location in patients with non-cardioembolic stroke using an acute dual study (ADS) cohort. Methods The ADS trial was conducted between May 2011 and June 2017 in Japan. The BMI classifications were those proposed by the World Health Organization classification: underweight, <18...
March 4, 2024: Internal Medicine
#29
JOURNAL ARTICLE
Karla Santo, Raul D Santos, Alysson Nathan Girotto, Josue Nieri, Frederico Monfardini, Priscila Raupp, Pedro Marton Pereira, Otavio Berwanger, M Julia Machline-Carrion
BACKGROUND: Statins consist of the main strategy to reduce dyslipidemia-related cardiovascular risk. Nevertheless, there is scarce evidence on the real-world statins use in primary care settings in low-middle-income countries. OBJECTIVE: We conducted a cross-sectional retrospective study using anonymized data routinely collected by community health workers in Brazil aimed to evaluate statin use and associated factors in a primary prevention population with cardiovascular risk enhancers...
February 20, 2024: Journal of Clinical Lipidology
#30
REVIEW
Esther Reijnders, Arnoud van der Laarse, L Renee Ruhaak, Christa M Cobbaert
In persons with dyslipidemia, a high residual risk of cardiovascular disease remains despite lipid lowering therapy. Current cardiovascular risk prediction mainly focuses on low-density lipoprotein cholesterol (LDL-c) levels, neglecting other contributing risk factors. Moreover, the efficacy of LDL-c lowering by statins resulting in reduced cardiovascular risk is only partially effective. Secondly, from a metrological viewpoint LDL-c falls short as a reliable measurand. Both direct and calculated LDL-c tests produce inaccurate test results at the low end under aggressive lipid lowering therapy...
March 1, 2024: Clinical Proteomics
#31
JOURNAL ARTICLE
Yuichi Ishizuka, Yohei Satake, Shingo Kimura, Shinichi Yamashita, Naoki Kawamorita, Akihiro Ito
AIMS: Statins are widely used to treat dyslipidemia and have been shown to reduce the risk of ischemic heart disease and cerebrovascular disease. The effects of statins on ischemia-induced overactive bladder (OAB) and the associated mechanisms were investigated in a rat model of chronic pelvic ischemia. METHODS: A pelvic ischemia model was created by iliac arterial injury (AI) and a high-fat diet using male Sprague-Dawley rats. Rats were assigned to 3 groups: control group, AI group, and AI + statin group...
March 1, 2024: Neurourology and Urodynamics
#32
REVIEW
N Katsiki, Td Filippatos, C Vlachopoulos, D Panagiotakos, H Milionis, A Tselepis, A Garoufi, L Rallidis, D Richter, T Nomikos, G Kolovou, K Kypreos, C Chrysohoou, K Tziomalos, I Skoumas, I Koutagiar, A Attilakos, M Papagianni, C Boutari, V Kotsis, C Pitsavos, M Elisaf, K Tsioufis, E Liberopoulos
Atherosclerotic cardiovascular disease (ASCVD) remains the main cause of death worldwide, and thus its prevention, early diagnosis and treatment is of paramount importance. Dyslipidemia represents a major ASCVD risk factor that should be adequately managed at different clinical settings. 2023 guidelines of the Hellenic Atherosclerosis Society focus on the assessment of ASCVD risk, laboratory evaluation of dyslipidemias, new and emerging lipid-lowering drugs, as well as diagnosis and treatment of lipid disorders in women, the elderly and in patients with familial hypercholesterolemia, acute coronary syndromes, heart failure, stroke, chronic kidney disease, diabetes, autoimmune diseases, and non-alcoholic fatty liver disease...
March 2024: Atheroscler Plus
#33
JOURNAL ARTICLE
Shruti Revankar, Jong Kun Park, Priyanka Satish, Anandita Agarwala
As the global population ages and cardiovascular risk factors rise, we can expect a continued increase in atherosclerotic disease. Low-density lipoprotein cholesterol (LDL-C) reduction is a cornerstone of cardiovascular risk reduction with strong, causal evidence indicating that the greatest benefit is derived from early and large decreases in LDL-C. Despite the adoption of statins as the backbone of lipid-therapy regimens, numerous studies and registry analyses reveal our collective inability to achieve LDL-C goals in high-risk patients...
March 2024: American journal of preventive cardiology
#34
JOURNAL ARTICLE
Chieh-Li Yen, Pei-Chun Fan, Cheng-Chia Lee, Jia-Jin Chen, Chao-Yu Chen, Yi-Ran Tu, Pao-Hsien Chu, Ching-Chung Hsiao, Yung-Chang Chen, Chih-Hsiang Chang
INTRODUCTION: Hypertriglyceridemia is the most prevalent dyslipidemia in patients with chronic kidney disease (CKD). However, research about fibrate treatment in CKD patients is limited, and assessing its benefits becomes challenging due to the frequent concurrent use of statins. Thus, this study is aimed to investigate the role of fibrate in CKD stage 3 patients with hypertriglyceridemia who did not receive other lipid-lowering agents. METHODS: This study enrolled patients newly diagnosed CKD3 with LDL-C<100mg/dL and had never received statin or other lipid-lowering agents from Chang Gung Research Database...
2024: Frontiers in Endocrinology
#35
REVIEW
Tea Shehu Kolnikaj, Rok Herman, Andrej Janež, Mojca Jensterle
Polycystic ovary syndrome (PCOS) manifests a multifactorial pathology characterized by polycystic ovaries, menstrual cycle disorders, varying degrees of hyperandrogenism, and an ad-verse metabolic risk profile. The position of hyperandrogenism in this syndrome has been extensively studied. A multitude of mechanisms place it in the position of cause but also of consequence; therefore, ongoing research efforts are focused on identifying medications that can effectively reduce levels of androgens in women with PCOS...
January 30, 2024: Medicina
#36
JOURNAL ARTICLE
Petros Spyridonas Adamidis, Matilda Florentin, Evangelos Liberopoulos, Amalia Despoina Koutsogianni, Georgia Anastasiou, George Liamis, Haralampos Milionis, Fotios Barkas
BACKGROUND AND AIM: Serum alkaline phosphatase (ALP) activity has been associated with atherosclerotic cardiovascular disease (ASCVD). We aimed to investigate the association of ALP with ASCVD in patients with dyslipidemia. METHODS: We conducted a retrospective cohort study including consecutive adults with dyslipidemia followed-up for ≥3 years (from 1999 to 2022) in the outpatient Lipid Clinic of Ioannina University General Hospital, Greece. The primary endpoint was the association between baseline ALP and incident ASCVD after adjusting for traditional risk factors (i...
February 15, 2024: Journal of Cardiovascular Development and Disease
#37
JOURNAL ARTICLE
Aseem Basha, Sivasubramanian Ramakrishnan
Indians have a pattern of atherogenic dyslipidaemia characterised by not so high LDL-C but elevated small, dense LDL-C, elevated triglyceride levels and low HDL-C levels. In addition, different lipid-lowering drugs exhibit pharmacokinetic variability in Indians, which may have implications on the optimum doses required to achieve the desired LDL-C levels. Currently the management of dyslipidaemia in Indians are based on the landmark trials, which largely included western population. This review focusses on major clinical trials of lipid lowering drugs with special reference to the Indian population...
February 20, 2024: Indian Heart Journal
#38
REVIEW
Felipe Placco Araujo Glina, Leonardo Lopes, Rodrigo Spinola E Silva, Eduardo Augusto Correa Barros, Bruno Biselli, Sidney Glina
PURPOSE: Statins are one of the most prescribed classes of drugs worldwide to treat hypercholesterolemia and dyslipidemia. By lowering the level of cholesterol, the use of statin could cause a reduction in testosterone levels. The objective was to evaluate whether the continued use of statins in patients with hypercholesterolemia causes a deficiency in testosterone and other sex hormones. MATERIALS AND METHODS: Systematic Review with Meta-analysis, performed in Embase, Medline and Cochrane databases, until May 2023; PROSPERO CRD42021270424protocol...
2024: International Braz J Urol: Official Journal of the Brazilian Society of Urology
#39
JOURNAL ARTICLE
Phong T Nguyen, Vishwajeet Singh, Vikram Thakur, Alok Kumar Dwivedi, Munmun Chattopadhyay
HMG-CoA reductase inhibitors (statins) are commonly used for dyslipidemia management to reduce the risk of cardiovascular disease (CVD). High-sensitivity C-reactive protein (hs-CRP) is an emerging systematic low-grade inflammatory marker associated with atherosclerotic CVD development. Despite racial/ethnic disparities in the use and response of statins and the anti-inflammatory effects of statins, the effectiveness of statins on inflammation and metabolic markers is unknown among Hispanics. We performed a retrospective cohort study using 150 adult patients scheduled for an annual physical exam at a family medicine clinic between January 1, 2021, and December 31, 2021...
February 18, 2024: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
#40
JOURNAL ARTICLE
N M Batt, B Rodrigues, S Bloom, R Sawhney, E S George, A Hodge, N Vootukuru, C McCrae, Surbhi Sood, S K Roberts, A Dev, S Bell, A Thompson, M C Ryan, W Kemp, P J Gow, Siddharth Sood, A J Nicoll
BACKGROUND AND AIM: The rising incidence of hepatocellular carcinoma (HCC) in Australia is related to increasing rates of metabolic-associated fatty liver disease (MAFLD). This study aimed to prospectively characterize the metabolic profile, lifestyle, biometric features, and response to treatment of HCC patients in an Australian population. METHOD: Multicenter prospective cohort analysis of newly diagnosed HCC patients at six multidisciplinary team meetings over a 2-year period...
February 18, 2024: Journal of Gastroenterology and Hepatology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
